# Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

> **NCT02171832** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy
- Liver Diseases

## Interventions

- **DRUG:** BI 1744 CL, low dose
- **DRUG:** BI 1744 CL, high dose

## Key facts

- **NCT ID:** NCT02171832
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171832, "Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02171832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*